Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Bio, Constant Systems Ink Marketing, Sales Pact

NEW YORK (GenomeWeb News) – Pressure Biosciences said today that it has struck a co-marketing and distribution pact with UK-based Constant Systems that will enable the companies to offer each other's products in North America and Europe.

Under the agreement, Pressure Bio will receive non-exclusive rights to market, sell, and distribute CS's high-pressure cell disruption equipment and consumables in the US, Canada, and Mexico.

The pact also enables CS to market, sell, and distribute Pressure Bio's pressure cycling technology in the UK and Ireland; Spain; Portugal; Italy; Norway; Sweden; Finland; Denmark; and Singapore. Pressure Bio noted that it has no sales and distribution channels in any of these countries beyond the US, while CS already has such channels in all of them.

The companies plan to co-market their products through trade shows, email campaigns, combined ads and webcasts, and they will make sales calls together.

Pressure Bio and CS also are discussing the possibility of expanding the agreement to include cooperative research, development, and manufacturing in the near future.

Pressure Bio President and CEO Richard Shumacher said in a statement that the companies' product lines "complement each other exceedingly well," and that they both have "fundamental scientific capabilities" that the other does not.

"PBI's PCT Platform uses certain patented pressure mechanisms to achieve small-scale, molecular level effects. CS's technology uses different, proprietary pressure mechanisms for larger-scale, non-molecular level processing. In a number of routine laboratory applications, such as protein extraction, both effects can be critical to success," said Schumacher.

The agreement will run until the end of 2013. Further terms of the alliance were not disclosed.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.